乳がん Breast Cancer の続き メーカー番号品名種類ト ナー数スホ ット数概要付属情報 Relapsed ER+ breast cancers with treatment Herceptin (Trastuzumab) eligible breast
|
|
- つねとき さかいざわ
- 5 years ago
- Views:
Transcription
1 Top Enabling Tissue-Based Biomarker Research ヒト組織アレイ一覧 v.1403 がん検体は全て手術またはバイオプシー由来です 採取から固定までの時間は 2~10 分です アレイ上の殆どのドナーは FFPE ブロックからの大きい切片および凍結サンプルが提供可能です アレイ内容は予告なしに変更する場合があります 各アレイの詳細情報はお問い合わせください 早見リンク 乳がんがん幹細胞大腸がん血液がん肺がん卵巣がん膵臓がん前立腺がん頭頸部癌食道がん 腎がん胃癌膀胱がん脳腫瘍マルチ腫瘍炎症性腸疾患関節リウマチ正常組織 乳がん Breast Cancer Breast Cancer Tissue Array 100 FFPE primary tumors, 10 matched nodal metastases, 10 normal breast samples. Single 1mm Approx 55 samples Stages I & II,, ER, PR, HER2 (IHC) approx 25 samples Stage III Breast cancer 100 with molecular data FFPE primary tumors, 10 matched nodal metastases, 10 normal breast samples. Single 1mm Approx 55 samples Stages I & II,, ER, PR, HER2 (IHC), HER2 (FISH), Ki67 approx 25 samples Stage III Breast paired nodal metastases FFPE primary tumors, 30 paired nodal metastases. Single 1mm, ER, PR, HER2 (IHC), Ki Breast cancers primary & paired distant metastases FFPE primary tumors, with 15 matched paired distant metastasis samples. 1mm, ER, PR, HER2 (IHC), Ki Breast cancer heterogeneity array FFPE donors, 3 each from 3-4 different primary tumor blocks per donor and paired nodal metastases. 1mm, ER, PR, HER2 (IHC), Ki Triple negative breast cancer (HH) Triple negative breast cancer B Triple negative breast cancer with follow up Relapsed ER+ breast cancers FFPE triple negative breast cancer donors. 1-2 /donor, 5 normal breast 1mm FFPE Triple negative breast cancers. Single 1mm FFPE Triple negative breast cancers. Duplicate 1mm <Same donors as in > FFPE ER+ breast cancers, Stages II and III. Single 1mm Diagnosis, ER, PR, HER2 ER, PR, HER2, Ki67 ER, PR, HER2, Ki67, metastases ost surgery (months), site of metastasis, (months) treatment & response (RECIST) Stage, ER, PR, HER2, Ki67 次のページに続く 1 / 8 ページ
2 乳がん Breast Cancer の続き メーカー番号品名種類ト ナー数スホ ット数概要付属情報 Relapsed ER+ breast cancers with treatment Herceptin (Trastuzumab) eligible breast cancer TMA with treatment Breast cancer prognosis array 450 with treatment Breast cancer prognosis array 2000 FFPE ER+ breast cancers Stage II & III (same donors as ). Single 1mm FFPE Trastuzumab eligible breast cancers. 10 Stage II, 30 Stage III. Adjuvant setting, Trastuzumab responders and non-responders. Duplicate 1mm FFPE breast cancers with follow-up. Includes ER+/ER-, HER2+/HER2-, triple negative. FFPE breast cancers with follow-up. Single 0.6mm Stage, ER, PR, HER2, Ki67, treatment, site of progression, response (RECIST) ER, PR, HER2, Ki67, metastases post surgery (months), site of metastasis, treatment & response (RECIST) ER, PR, HER2, Ki67, metastases post surgery (months), site of metastasis, (months) treatment & response (RECIST) Age, Diagnosis, Grade, pt, pn, all nodes, positive nodes, BRE grade, (raw & tumor specific), hormonal therapy (Y/N), cytotoxic therapy (Y/N), pre-operative chemotherapy (Y/N) がん幹細胞 Cancer Stem Cells Human Cancer Stem Cell (CSC) cytoinclusion array with matched CSC generated xenografts FFPE CSCs isolated from human primary tumors. Matched xenografts from selected CSCs. Cancer types: Breast, colon, lung, glioblastoma and melanoma. Age, gender 大腸がん Colon Cancer メーカー番号品名種類ト ナー数スホ ット数概要付属情報 Colorectal Cancer Tissue Array Colon cancer 100 with molecular data Colon cancer progression array Colon cancer heterogeneity array FFPE primary tumors (Mainly advanced stage tumors III & IV) and 5 normal colon samples. FFPE primary tumors (Mainly advanced stage tumors III & IV), 5 normal colon samples. FFPE adenoma and 10 normal colon tissues. 50 low grade adenoma, 50 high grade adenoma, 50 pt2, 50 pt3, 50 nodal metastases and 50 liver metastases. FFPE donors, 3 each from 3-4 different primary tumor blocks per donor and paired nodal metastases. 1mm status, BRAF, p53 (tumor & adjacent), beta catenin (normal adjacent) status, 次のページに続く 2 / 8 ページ
3 大腸がん Colon Cancer の続き Colon adenoma array FFPE Approx. 25 high grade & 75 low grade Age, gender & grade adenomas Colon cancer liver metastases array FFPE Primary CRC (Stage IV) with matched liver metastases & 5 unmatched liver metastases. 1mm Colon cancer paired nodal metastases Colon cancer Stage II-III with KRAS data Colon cancer Stage IV with KRAS data Colon cancer with Cetuximab treatment Colon cancer with bevacizumab treatment II Colon cancer prognosis array 300 with treatment Colon cancer prognosis array 600 FFPE primary tumors, 30 paired nodal metastases. 1mm FFPE CRC with KRAS mutation data (WT and mutations G12V, G13D, G12D, G12C, G12A). Triplicate 1mm FFPE CRC with KRAS mutation data (WT and mutations G12V, G13D, G12D, G12C, G12A). Triplicate 1mm FFPE CRC with follow up including cetuximab treatment & response. Stage IV CRC, metastatic. KRAS WT, EGFR IHC data. Duplicate 1mm FFPE CRC with KRAS mutation status, follow up including bevacizumab treatment (metastatic & adjuvant) & response. Stage II, III CRC (adjuvant setting) & Stage IV (metastatic setting). Duplicate 1mm FFPE colon cancers. 80 donors Stage I/II, 200 donors Stage III/IV, 15 matched & unmatched liver metastases, 8 normal colons. Single 1mm FFPE colon cancers. 175 donors Stage I/II, 400 donors Stage III/IV, 15 matched & unmatched liver metastases, 10 normal colon. Single 1mm status, EGFR (IHC), site of met & months post surgery, treatment & response (RECIST) status, site of met & months post surgery, treatment & response (RECIST), site of met, treatment & response (RECIST), site of met, treatment & response (RECIST) 血液がん Hematological Cancers Multiple Myeloma 15 FFPE plasmacytoma samples from bone marrow. Stages (Salmon and Durie): 1, 2, 3A. Single Age, gender, diagnosis, stage, organ 0.6mm Non-Hodgkin s Lymphoma FFPE diffuse large B cell lymphoma, 20 follicular Age, gender, diagnosis, location lymphoma, 10 CLL/SLL. Single 1mm Non-Hodgkin s Lymphoma with diagnostic and follow up FFPE diffuse large B cell lymphoma, 20 follicular lymphoma, 10 CLL/SLL with follow up & diagnostic IHC markers. Single 1mm <Same donors as > Age, gender, diagnosis, location. IHC diagnostic markers, treatment, response & Diffuse large B cell lymphoma (DLBCL) FFPE diffuse large B cell lymphoma. Single 1mm Age, gender, diagnosis, location 次のページに続く 3 / 8 ページ
4 血液がん Hematological Cancers の続き メーカー番号品名種類ト ナー数スホ ット数概要付属情報 Diffuse large B cell lymphoma (DLBCL) with diagnostic and follow up FFPE diffuse large B cell lymphoma with follow up & diagnostic IHC markers. Single 1mm <Same donors as > Age, gender, diagnosis, location. IHC diagnostic markers, treatment, response & Recurrent Diffuse large B FFPE diffuse large B cell lymphoma (recurrent) Age, gender, diagnosis, cell lymphoma (DLBCL) with follow up & diagnostic IHC location. IHC diagnostic markers. markers, treatment, response & Myelodisplastic syndrome FFPE Myelodisplastic syndrome (MDS), single Age, gender, diagnosis (MDS) 1mm AML FFPE AML, duplicate 0.6mm Diagnosis 肺がん Lung Cancer Lung Cancer Tissue Array (NSCLC) 130 FFPE lung cancers (NSCLC). Stages I-III, Adenocarcinoma (60 samples), squamous cell carcinoma (50) lother sub-types (20). Single 1mm KRAS mutation, EGFR mutation, c-met (IHC) Lung Cancer Tissue Array FFPE lung cancers (NSCLC). Stages I-III, (NSCLC) 250 Adenocarcinoma (100 samples), squamous cell carcinoma (120), other sub-types (30). Single 1mm KRAS mutation, EGFR mutation, c-met (IHC) Lung Cancer Tissue Array (NSCLC) 350 FFPE lung cancers (NSCLC). Stages I-III, Adenocarcinoma (140 samples), squamous cell carcinoma (160), other sub-types (50). KRAS mutation, EGFR mutation, c-met (IHC) Lung cancer heterogeneity array FFPE donors, 3 each from 3-4 different primary tumor blocks per donor. 1mm KRAS mutation, EGFR mutation, c-met (IHC) Lung cancer EGFR diagnostics TMA FFPE Lung cancers with EGFR (IHC, exon sequencing, FISH) and KRAS (sequencing) data. Duplicate 0.6mm pt, pn, UICC stage, EGFR (IHC), EGFR mutation (sequencing), KRAS mutation (sequencing), Gene EGFR (avg.), centromere (avg), result, EGFR=/> Small cell lung cancer (SCLC) FFPE SCLC donor samples (including 6 with follow up data) plus 10 normal lung Duplicate 0.6mm Age, gender, diagnosis. Follow up data on selected samples includes smoking status, site of met, treatment and Lung cancer prognosis array 400 with treatment FFPE NSCLC donor samples. Stages I-III, Adenocarcinoma (140 samples), squamous cell carcinoma (160) and other sub-types (50). Single 1.0mm treatment &. KRAS mutation, EGFR mutation, c-met (IHC). Survival data for all samples, treatment for 80 samples 次のページに続く 4 / 8 ページ
5 肺がん Lung Cancer の続き Lung cancer prognosis array 400 with treatment FFPE NSCLC donor samples. Stages I-III, Adenocarcinoma (140 samples), squamous cell carcinoma (160) and other sub-types (50). Single 1.0mm treatment &. KRAS mutation, EGFR mutation, c-met (IHC). Survival data for all samples, treatment for 80 samples Lung cancer prognosis array 480 FFPE NSCLC donor samples. 90 ADC, 280 SCC, 40 bronchioloalveolar, 70 large cell, 4 neuroendocrine. Single 0.6mm *Release in 1Q 2014 TNM, (tumor specific & raw ), radiotherapy (Yes/No), Chemotherapy (Yes/No). 卵巣がん Ovarian Cancer Ovarian Cancer 100 FFPE ovarian cancers. 76 serous papillary carcinoma, 9 Adenocarcinoma NOS, 2 Clear Age, diagnosis, grade, TNM, stage cell adenocarcinoma, 4 Endometrioid Adenocarcinoma, 9 Mucinous Adenocarcinoma. Stages III/IV. Duplicate 1.0mm Ovarian cancer prognosis array 100 with treatment FFPE ovarian cancers. Duplicate 1mm <Same donors as > Age, diagnosis, grade, TNM, stage, setting (adjuvant/metastatic), treatment, follow up (RECIST),, KRAS mutation, AKTI mutation 膵臓がん Pancreatic Cancer Pancreatic cancer primary & matched metastases FFPE pancreatic adenocarcinoma with paired nodal metastases and 2 normal samples. Age, diagnosis, grade, TNM, stage Pancreatic Cancer prognosis array FFPE pancreatic adenocarcinomas. Single 1mm Age, diagnosis, grade, TNM, stage, (raw & tumor specific) 5 / 8 ページ
6 前立腺 Prostate Cancer Prostate Cancer Array 150 FFPE prostate adenocarcinomas. 1mm from one or more blocks per donor Prostate cancer array (includes hormone FFPE prostate cancers, adenocarcinoma including hormone refractory. Gleason sum refractory) 6-9. Duplicate 1mm Prostate cancer heterogeneity array FFPE donors, 3 each from 3-4 different primary tumor blocks per donor. 1mm *Release in 1Q Prostate cancer progression array 100 FFPE BPH, PIN, pt2b, pt3b, hormone refractory, Gleason 8-9, normal control tissues. Single 1mm Hormone refractory prostate cancers FFPE hormone refractory prostate cancers. Biochemical criteria: Testosterone level lower than 0.5, and increases in PSA higher than 2 in two serial determinations separated by one week. Clinical criteria: radiological or bone scan progression Duplicate 1mm Prostate cancer prognosis array 500 FFPE prostate cancers with 5 year follow up. Single 0.6mm Age, diagnosis, pt, pn, Gleason scoring, PSA level, censor recurrence 頭頸部癌 Head and Neck Cancer Head & neck cancer 80 FFPE head & neck cancers. Tongue (15), oral Age, gender, location, TNM cavity (15), pharynx (28), lip (25). Single 1mm Head & neck cancer 80 with follow up data FFPE head & neck cancers. Tongue (15), oral cavity (15), pharynx (28), lip (25). Single 1mm <Same donors as > Age, gender, location, TNM, smoking status, treatment, PFS, overall Head & neck cancer 80 with follow up data & HPV status FFPE head & neck cancers. Single 1mm Age, gender, location, TNM, smoking status, treatment, PFS, overall. HPV status Head & neck cancer 95 FFPE head & neck cancers. Larynx (70), tongue (14) other sites (9). Single 1mm Age, gender, location, grade,, smoking status Head & neck cancer 95 with follow up data FFPE head & neck cancers. Larynx (70), tongue (14) other sites (9). <Same donors as in > Age, gender, location, diagnosis, grade, TNM, treatment, response (RECIST), Head & neck cancer 95 with follow up data & HPV status FFPE head & neck cancers. Larynx (70), tongue (14) other sites (9). <Same donors as in >. Age, gender, location, diagnosis, grade, TNM, treatment, response (RECIST),, HPV status 6 / 8 ページ
7 食道がん Esophageal Cancer Esophageal cancer 100 FFPE primary tumors, 20 matched nodal metastases, 20 normal tissues. 25 adenocarcinoma, 35 small cell carcinoma. 腎がん Renal Cancer Renal Cell Carcinoma 60 FFPE primary renal cell carcinomas. Mix of grades & stages. 胃癌 Gastric Cancer Gastric Cancer 90 FFPE gastric cancers. Mix of diffuse & intestinal types, adenocarcinoma, antrum, body GE junction. Single 1mm TNM Gastric cancer 90 with FFPE gastric cancers. Mix of diffuse & intestinal follow up data types, adenocarcinoma, antrum, body GE junction. <Same donors as > TNM, treatment, response, 膀胱がん Bladder Cancer Bladder Cancer 90 FFPE bladder cancers, 7 matched metastases, 3 unmatched metastases, 10 normal bladder TNM samples. T1-4a, N0-3, M0-1. Single 1mm Bladder Cancer 90 with follow up data FFPE bladder cancers, 7 matched metastases, 3 unmatched metastases, 10 normal bladder with follow up data (treatment, response, ). <Same donors as > TNM, treatment, response, 脳腫瘍 Brain Tumor Glioblastoma Multiforme 100 FFPE Grade IV GBM including recurrences and radiotherapy data, 5 normal. Duplicate 0.6mm Age, gender, radiotherapy (yes/no) Medulloblastoma 50 FFPE medullloblatsoma, 10 PNETs. Medulloblastoma WHO grade IV, spnet WHO grade IV. Duplicate 0.6mm Age, gender, diagnosis 7 / 8 ページ
8 マルチ腫瘍 Multi-Tumor Multi Tumor 120 FFPE tumor types, 12 donor samples each. Tumor types: Breast, Age, Gender, Diagnosis, Tumor Grade & Stage Colorectal, Prostate, Lung, Ovarian, Head & Neck, Melanoma, Bladder, Renal Cell and Pancreatic Multi Tumor 450 FFPE tumor types, donor samples each. Duplicate 1mm Tumor types: Breast, Colon, Lung (NSCLC), Lung (SCLC), Prostate, Ovarian, Gastric, Head & Neck, Kidney, Melanoma, Bladder, Endometrial, Lymphoma, Thryroid. Age, Gender, Diagnosis, Tumor Grade & Stage 炎症性腸疾患 Inflammatory Bowel Disease Inflammatory Bowel Disease (Crohn's disease & ulcerative colitis) FFPE Crohn's disease & 10 ulcerative colitis, single 1mm Age, gender, diagnosis 関節リウマチ Rheumatoid Arthritis Rheumatoid Arthritis FFPE rheumatoid arthritis samples. Single 1mm Age, gender, diagnosis 正常組織 Normal Tissues Normal Tissue 96 FFPE normal human tissues, 3 donors each. Age, gender Tissue types: Stomach (fundus), stomach (muscle), heart, skin, uterus (myometrium), exocervix, lymph node, spleen, thymus, Ileum, colon descendens, gallbladder, liver, ureter, parotid gland, kidney (cortex), kidney (medulla), prostate, testis, ovary, lung, (parenchyma), breast (glands), endocervix, endometrium, placenta (early), seminal vesicle, adrenal gland, thyroid, cerebellum (cortex), cerebrum, urinary bladder (urothelium), fallopian tube Normal breast FFPE Single 1mm Age Normal colon FFPE Single 1mm Age, gender Normal prostate FFPE Single 1mm Age Normal lung/bronchus FFPE Single 1mm Age, gender Normal bladder/urothelium FFPE Single 1mm Age, gender 8 / 8 ページ
Table 1. Numbers of Cancerous Pleurisy Cases According to Primary Site Table 2. Histological Type of Lung Carcinoma with Cancerous Pleurisy at Autopsy
Clinicopathological Studies on Cancerous Pleurisy, with Emphasis on Extra-Pulmonary Malignancy Table 1. Numbers of Cancerous Pleurisy Cases According to Primary Site Table 2. Histological Type of Lung
More informationTreatment Architecture 2018 Japan / United States / Western Europe
Treatment Architecture 2018 Japan / United States / Western Europe 12 月発刊レポートのご案内 Treatment Architecture 2018 12 月発刊レポートの一覧 12 月は下記の 5 がん種のレポートを発刊しております 最新の調査結果をご活用ください 最新の調査では昨年までの調査項目を引き継ぎつつ 新しい作用機序の薬剤
More information1_2.eps
第32回 日本頭頸部癌学会ランチョンセミナー6 Pre-Meeting Abstract FDG-PET の頭頸部癌における臨床的有用性 司会 長 放射線治療センター長 講演 1 耳鼻咽喉科 部長 講演 2 PETセンター長 岡村 光英 先生 日時 2008年6月13日 金 12:00 13:00 会場 ハイアットリージェンシー東京 共催 第32回 日本頭頸部癌学会 日本メジフィジックス株式会社 136-0075
More information食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
More informationVENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%
More information目次頁
がんの統計 15 CACER STATISTICS I JAPA 2015 公益財団法人がん研究振興財団 Foundation for Promotion of Cancer Research 目次頁 4 11 1 2015 14 2 2014 15 3 2014 16 4 2014 17 5 75 2014 18 22 6 2011 23 7 2011 24 8 2011 25 9 2003 2005
More information; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9
32, 21-25, 2012 CASLE 1 1 80 26 6 5 4 cm 1 2 CEA 3 4 CEA 2 44 22 2 3 1.5 cm 22 1. 1 ; 6 5 4 cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml 0-40 5 Mφ 6 7, 8 9 23 6. ; 9. ; 7. ; 10. ; 8. 7 10 CK3 CK3 24 1,2 3 2 8% 4,5
More informationISSN がんの統計 18 CANCER STATISTICS IN JAPAN 2018 公益財団法人がん研究振興財団 Foundation for Promotion of Cancer Research
ISS 2433-3212 がんの統計 18 CACER STATISTICS I JAPA 2018 公益財団法人がん研究振興財団 Foundation for Promotion of Cancer Research 4 11 1 2018 14 2 2017 15 3 2017 16 4 2017 17 5 75 2017 18 22 6 2014 23 7 2014 24 8 2014 25
More information_06.indd
30, 35-39, 2010 0.15% 1 C 40 20 1 cm 5 mm WBC 9,400, RBC 259 10 4, Hb 8.5 g/dl, Ht 25.5%, Plt 29 10 4, BUN 116 mg/dl, Cr 7.9 mg/dl, 125 mg/dl, HbA1c 4.3%, ft3 1.97 pg/ml, ft4 1.05 ng/dl, TSH 1.09 μiu/ml,
More informationISSN がんの統計 17 CANCER STATISTICS IN JAPAN 2017 公益財団法人がん研究振興財団 Foundation for Promotion of Cancer Research
ISS 2433-3212 がんの統計 17 CACER STATISTICS I JAPA 2017 公益財団法人がん研究振興財団 Foundation for Promotion of Cancer Research 4 11 1 2017 14 2 2016 15 3 2016 16 4 2016 17 5 75 2016 18 22 6 2013 23 7 2013 24 8 2013 25
More informationCHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
More information橡
TP T-13i AST ALT ALP Y CTP LOH CHE CRP 8.7 id 0.4 mg/d 21 AWL 131U/L 257 LU/L 12 111/L 234 11J/L 344 IU/L 0.30 mid No K a BUN ORE UA 142 meq/1 4.3 meqa 108 meqa 15.8 met! 0.71 mg/di 5.0 mg/d CEA 5_5 n8/m1
More informationレントゲン X線
PET ( TIAN Mei ) PET 100 PET PET PET PET PET Positron Emission Tomography (PET) PET Positron Emission Tomography CT PET FDG Glucose and 18 F-FDG 18 F-FDGFDG CH3OH O CH3OH O OH OH OH OH OH OH OH 18 F *FDG
More information2
2 3 4 5 6 7 8 9 1 2 3 4 5 10 11 12 1 2 1 2 1 2 13 14 3 17 15 1 2 3 D Usefulness of Tc-99m MIBI SPECT in predicting multidrug resistance gene expression level in non-small cell lung cancer a preliminary
More informationMicrosoft PowerPoint - ⑦大上講師説明資料.ppt
広島大学 新技術説明会 8/20 大阪 胃癌診断のための 高感受性血清腫瘍マーカー 広島大学大学院医歯薬学総合研究科分子病理 講師 大上 直秀 教授 安井 弥 研究背景 胃癌は近年減少してきているとはいえ 尚 最も頻度の高い癌の一つであり この克服は現代社会の最大の課題である 分子病理学研究室では 胃癌の発生 進展のメカニズムを解析し 胃癌の病態解明を行っている さらに そこから得られた知見をもとに
More informationPowerPoint プレゼンテーション
再発腫瘍の個別化医療 京都大学医学研究科標的治療腫瘍学講座 新倉直樹 乳癌の治療におけるバイオマーカー 原発腫瘍 Months/years 再発腫瘍 Months/years Progression ER PgR HER2 Ki67? ER PgR HER2 腫瘍の性格や治療選択が原発腫瘍もしくは再発腫瘍内で同じでいいのか? Abbreviations: ER, oestrogen receptor;
More information口腔癌の早期発見のために For the early detection of oral cancer Kazumasa Sugihara Department of Maxillofacial Diagnostic and Surgical Science, Field of Oral and M
Title 口腔癌の早期発見のために Author(s) 杉原, 一正 Citation 鹿児島大学歯学部紀要, 34: 3-11 Issue Date 2014 URL http://hdl.handle.net/10232/20682 http://ir.kagoshima-u.ac.jp 口腔癌の早期発見のために For the early detection of oral cancer Kazumasa
More informationCOTETS Page History of Cancer Control in Japan 4 11 Figures and Tables 1 Projection of Cancer Mortality and Incidence in umber of Deaths, by
ISS 2433-3212 がんの統計 17 CACER STATISTICS I JAPA 2017 公益財団法人がん研究振興財団 Foundation for Promotion of Cancer Research COTETS Page History of Cancer Control in Japan 4 11 Figures and Tables 1 Projection of Cancer
More informationPowerPoint プレゼンテーション
* ** 117,320 70,293 109,140 49,830 93,402 45,744 60,986 31,875 47,318 28,829 45,367 18,186 29,025 12,838 27,822 11,970 20,734 10,823 19,994 10,336 * 2007 ** 2011 65% 25% 9 DNA P53, ATM G1 S G2 G1 M 1
More informationがんの統計 16 CANCER STATISTICS IN JAPAN 216 公益財団法人がん研究振興財団 Foundation for Promotion of Cancer Research 4 11 1 216 14 2 215 15 3 215 16 4 215 17 5 75 215 18 22 6 212 23 7 212 24 8 212 25 9 26 28 26 27 1 28
More informationISSN がんの統計 17 CANCER STATISTICS IN JAPAN 2017 公益財団法人がん研究振興財団 Foundation for Promotion of Cancer Research
ISSN 2433-3212 がんの統計 17 CANCER STATISTICS IN JAPAN 17 公益財団法人がん研究振興財団 Foundation for Promotion of Cancer Research 4 11 1 17 14 2 16 15 3 16 16 4 16 17 5 75 16 18 22 6 13 23 7 13 24 8 13 25 9 6 8 26 27 8
More informationuntitled
19 CSPOR CRC/2009.8.8-9 2009 8 8 ( ) - CSPOR CRC SEMINAR- twatanab@oncoloplan.com http://www.oncoloplan.com - Toru Watanabe MD - 2 Phase I: Dose Finding trial Phase II : Efficacy and Safety trial Phase
More information02-Preface†i5†j
Past, Present, and Future of Radiation Oncology Masahiro Hiraoka, M.D. Department of Therapeutic Radiology and Oncology, Kyoto University Graduate School of Medicine NICHIDOKU-IHO Vol. 50 No. 1 98 104
More informationISSN がんの統計 18 CANCER STATISTICS IN JAPAN 2018 公益財団法人がん研究振興財団 Foundation for Promotion of Cancer Research
ISSN 2433-3212 がんの統計 18 CANCER STATISTICS IN JAPAN 18 公益財団法人がん研究振興財団 Foundation for Promotion of Cancer Research 4 11 1 18 14 2 17 15 3 17 16 4 17 17 5 75 17 18 22 6 14 23 7 14 24 8 14 25 9 6 8 26 27 8
More informationuntitled
twatanab@oncoloplan.com http://www.oncoloplan.com I II - III IV Fig 3. Survival curves overall and according to response Bruzzi, P. et al. J Clin Oncol; 23:5117-5125 25 Copyright merican Society of Clinical
More information1) Asa, S. L., et al.: Immunohistochemical localization of neuron-specific enolase in the human hypophysis and pituitary adenoma, Arch. Pathol. Lab. Med., 108: 40 `43, 1984. 2) Chi, B. H. and Kim, R. C.:
More informationTitle 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date URL
Title 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date 1958-01 URL http://hdl.handle.net/2433/111559 Right Type Departmental Bulletin
More information3) Beresford SAA, Weiss NS, Voigt LF, et al: Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349: 458-461, 1997 4) Daly
More informationCONTENTS Page History of Cancer Control in Japan 4 11 Figures and Tables 1 Projection of Cancer Mortality and Incidence in Number of Deaths,
がんの統計 15 CANCER STATISTICS IN JAPAN 215 公益財団法人がん研究振興財団 Foundation for Promotion of Cancer Research CONTENTS Page History of Cancer Control in Japan 4 11 Figures and Tables 1 Projection of Cancer Mortality
More information日本消化器外科学会雑誌第30巻第3号
Key words : gastric cancer, progltostic factor. multivariate analysis Factors selected after Coffelation- after Stepwise rnitrally check check H o s t l A g e C O 2 S e x C O 3 Pre-op. compliation O Treatment
More informationA05002 A05005 A05017 200. CEA B. CA-19 C. CA-125 D. HCG E. α-fetoprotein Papillary serous carcinoma α fetoprotein. 22-8 05019 A05039 KK A05039 KK A 17-year-olf high school senior presents to his local
More information目 次 はじめに... 独立行政法人国立病院機構北海道がんセンター臨床検査科病理主任平紀代美 Ⅰ. Liquid-based cytology(lbc) とは... 1 Ⅱ. 体腔液検体処理方法... 1 Ⅲ. 固定液の違いによる標本の違い (BD サイトリッチ レッド保存液 or BD サイトリッ
目 次 はじめに... 独立行政法人国立病院機構北海道がんセンター臨床検査科病理主任平紀代美 Ⅰ. Liquid-based cytology(lbc) とは... 1 Ⅱ. 体腔液検体処理方法... 1 Ⅲ. 固定液の違いによる標本の違い (BD サイトリッチ レッド保存液 or BD サイトリッチ ブルー保存液 )... 2 Ⅳ. BD サイトリッチ レッド保存液による thin-layer 標本の細胞所見の特徴...4
More informationuntitled
21 1 26 1 US6759035University of Southern California 1. A method for decreasing graft rejection of a solid organ by a recipient comprising: a) isolating peripheral blood mononuclear cells (PBMC) from a
More informationPROGNOSTIC FACTORS OF LATERAL WALL OROPHARYNGEAL SQUAMOUS CELL CARCINOMA TOMOHIKO NIGAURI, M.D., SHIN ETSU KAMATA, M.D., KAZUYOSHI KAWABATA, M.D. MUNE
PROGNOSTIC FACTORS OF LATERAL WALL OROPHARYNGEAL SQUAMOUS CELL CARCINOMA TOMOHIKO NIGAURI, M.D., SHIN ETSU KAMATA, M.D., KAZUYOSHI KAWABATA, M.D. MUNENAGA NAKAMIZO, M.D., KATSUFUMI HOKI, M.D., HIROKI MITANI,
More information日本消化器外科学会雑誌第23巻第2号
Key words: carcinoma of the pancreatic head, carcinoma of the periampullary region, operative results of the pancreatic duodenal carcinoma, mode of tumor spread of the pancreatic duodenal carcinoma, factors
More informationuntitled
19CRC/2009.8.8-9 T0 T1 T2 T3 T4 M0 N0 M1 19CRC 2009.8.8 1 2 N1 N2 N3 Stage 0 Stage I Stage IIA Stage IIB Stage IIIA Stage IIIB Stage IIIC Stage IV Tis 3 4 5 6 1 19CRC/2009.8.8-9 7 8 Subtype of Breast Cancer
More informationFine needle aspiration cytology in gynecologic malignancy Nao KINO1), M. D., Masaki FUJIMURA1), M. D., M. I. A. C., Takako SHIRAI1), M. D., M. I. A. C
Fine needle aspiration cytology in gynecologic malignancy Nao KINO1), M. D., Masaki FUJIMURA1), M. D., M. I. A. C., Takako SHIRAI1), M. D., M. I. A. C., Michiko TAKAHASHI1), M. D., M. I. A. C., Katsutoshi
More information<4D F736F F F696E74202D CF697A E58A774A B5A8F7090E096BE89EF816992C A81464B E707074>
短期間で癌を発生させる 新規モデル動物 名古屋市立大学大学院医学研究科教授津田洋幸 1 研究背景 動物への発がん物質の投与による化学発がんでは がんの発生に約半年から一年の期間を要する 飼育期間の短縮はコスト削減に大きく貢献 短期間で発癌するヒトがんのモデル動物を開発した 2 従来の化学発がんモデル 肺がんモデル化学発がん (25-30 週間 ) DHPN NNK 4-NQO 乳がんモデル化学発がん
More information9 : 00 11 : 00 12 : 00 12 : 10 12 : 50 13 : 30 14 : 40 16 : 00 17 : 00
9 : 00 11 : 00 12 : 00 12 : 10 12 : 50 13 : 30 14 : 40 16 : 00 17 : 00 ポスターについて 1. ポスター 貼 付 用 の 展 示 ボードは 縦 180 横 90cm の 大 きさです 2. 演 題 名 発 表 者 名 所 属 を 明 記 したもの(20 70cm) をご 用 意 ください 実 際 使 用 できるスペースは 155
More informationuntitled
260 250 200 150 10 100 50 0 1960 1965 1970 1975 1980 1985 1985 1995 2000 2005 25% 56% 66% 60% 90 80 70 60 50 40 30 20 10 0 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 4 1999 1990 2003 2005 2010 500,000 70,000 100,000
More informationTable 1 Laboratory findings on admission Figure 2. Clinical course after admission 1-a 1-b 1-c 3-a 3-b 3-c Figure 1. CT findings on first admission: S
FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF Vol. 32, pp. 105 110, 2004 FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF 1 1 1 1 1 1 1 1 2 2 1 1 16 4 13 72 CRP
More information生命倫理100_資料4-7
26 27 Single cell clones picked from swaps12p36 (18) Single cell clones picked from swaps12p18 (24) 1.3% (p0) 1.1% (p58) 28 29 Outline 30 31 32 33 34 Columbia, The New York Stem Cell Foundation Oocyte
More information目次頁
がんの統計 15 CANCER STATISTICS IN JAPAN 215 公益財団法人がん研究振興財団 Foundation for Promotion of Cancer Research 目次頁 4 11 1 215 14 2 214 15 3 214 16 4 214 17 5 75 214 18 22 6 211 23 7 211 24 8 211 25 9 23 25 26 27 1
More informationCHEMOTHERAPY APR. 1984
VOL.32 S-3 CHEMOTHERAPY dihydro-4-oxo-7-(1-piperazinyl)-1, 8-naphthyridine- CHEMOTHERAPY APR. 1984 VOL.32 S-3 CHEMOTHERAPY Table 1 Implantation rates and post- implantation survival rates in females mated
More information<4D F736F F F696E74202D2094AD955C BD82BF82C482F F6E E63655B93C782DD8EE68
Polysomy 17 in Breast Cancer 2009 年 10 月 15 日 たちてん web conference 前回提示した症例 58 歳閉経後女性 右 MMK(T4bN1M0 Stage IIIB) に対して H11.8 月 Bt+Mn+Ax 試行 His ; IDC, t= 58mm, n= 9/22, HG3, ER/PR/HER2 = -/+/0 Adj ; ECx6 TAM
More informationThe vaginal smears obtained from a 63-year-old woman revealed malignant features such as hyperchromasia, coarse gnanular chromatin and enlarge- ment of N/C ratio. Tadpole and fiber shaped malignant cells
More information日本消化器外科学会雑誌第29巻第9号
Table 1 Oligonucleotide primers used for RT-PCR and internal probes used for Southern blot hybridization Cytokine Primer Sequence (5'-3') 5' 3' Internal probe s' 3' Internal probe 5' 3' Internal probe
More informationHairy cell leukemia Hepatosplenic T-cell lymphoma Mycosis fungoides Sézary syndrome Lymphomatoid papulosis Primary cutaneous gd T-cell lymphoma Peripheral T-cell lymphoma, NOS Angioimmunoblastic T-cell
More informationMetastatic Carcinoma of the Sigmoid Colon to the Thyroid Gland Yuhei SHIBUTANI 1), Daisuke INOUE 1), Toshihiko YOKOTA 2), Jyoji OKUDA3) and Toru MORI3
Metastatic Carcinoma of the Sigmoid Colon to the Thyroid Gland Yuhei SHIBUTANI 1), Daisuke INOUE 1), Toshihiko YOKOTA 2), Jyoji OKUDA3) and Toru MORI3) 1) Department of Internal Medicine, Hyogo Prefectural
More informationスライド 1
QOL 1 Goldberg, JCO 22:23-30, 2004 N9741: Oxaliplatin in First Line (US) IR 200 mg/m 2 OX 85 mg/m 2 every 3 weeks Efficacy IFL FOLFOX4 > IFL IROX FOLFOX4 IROX OS TTP RR 15.0 mo 6.9 mo 31 % P=0.0001 P=0.0014
More information日本消化器外科学会雑誌第25巻第12号
Key words: poorly differentiated gastric carcinoma, medullary gowth pattern, Grimelius staining, immunohistochemistry, c-erbb-2 Fig. 2 Acinar type tumors. Several neoplastic cells aggregated and formed
More informationPostoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on validated prognotic nomogram and risk group stratification system
弘前大学医学部泌尿器科学教室 腎癌術後フォローアップ プロトコール Since 2005.9 参考文献 Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on validated prognotic nomogram and risk
More information計算機生命科学の基礎II_
Ⅱ 1.4 atsushi_doi@cell-innovator.com 812-8582 3-1-1 8 806 http://www.cell-innovator.com BioGPS Connectivity Map The Cancer Genome Atlas (TCGA); cbioportal GO DAVID, GSEA WCGNA BioGPS http://biogps.org/
More information_統合化推進プログラム_金久チーム_サイトビジット資料
ライフサイエンスデータベース統合推進事業統合化推進プログラム ゲノム 疾患 医薬品のネットワークデータベース実施状況 京都大学化学研究所 金久 實 2018 年 8 月 22 日サイトビジット資料 KEGG NETWORK とは NAR DB Issue 2017 KEGG: new perspectives on genomes, pathways, diseases and drugs From
More information基調講演 デジタル技術と人が作る 広域病理細胞診断支援網のあり方
ワークショップ 4 病理診断における精度管理の意義と実際 : 今 病理医がなすべきこと 2. 分子病理診断の標準化と精度管理における課題と取り組み 畑中豊 1,2, 松野吉宏 1,2 北海道大学病院 1 病理部, 2 コンパニオン診断研究部門 2012 年 4 月 28 日 現在の分子病理診断 病理診断 形態診断 分子診断 補助診断 タンパク発現検索(IHC 法 ) 遺伝子転座/ 欠失検索等 (FISH
More informationSquamous papilloma
山 口 大 学 医 学 部 病 理 腫 瘍 総 論 第 6 回 第 5 回 のおさらい 浸 潤 と 転 移 - 悪 性 腫 瘍 の 最 大 の 特 徴 リンパ 行 性 転 移 血 行 性 転 移 播 種 病 期 (ステージについて) 病 期 (ステージ)とは TNM 分 類 のしくみ 良 性 腫 瘍 と 悪 性 腫 瘍 のちがい 肉 眼 的 相 違 点 と 組 織 学 的 相 違 点 本 日 の 講
More information1) Michaelis L. Biochem Z., 59, 78, 1914. 2) Ferris H. C. Dent. Cosmos Phila., 63, 10, 93, 1921. 3) Bloomfield A. L. Bull Johns Hopk. Hosp. Bait., 31, 118, 1920. 4) Starr H. C. J. Biol. Chem. Bait., 54,
More information*Criteria 1) B-marker positive 2) Variability in nuclear size and shape 3) Giant cells and multinucleated cells
*Criteria 1) B-marker positive 2) Variability in nuclear size and shape 3) Giant cells and multinucleated cells Abbreviation: LC=large cleaved nuclei, LNC=large non-cleaved nuclei, IMBL=immunoblastic nuclei,
More informationToshiya CHIHARA,M.D. and Takakazu SHIBATA, M.D.
Toshiya CHIHARA,M.D. and Takakazu SHIBATA, M.D. Fig. 1 Clinical Appearrance on the Head and Face of Case 1 on the First Arrival Fig. 2 Clinical Appearrance on the Shoulder and Arm of Case 1 on the First
More informationCT 5 HE PSA PAP 6 1 1
45 2140 145 2006 70 PSA 33.32 ng/ml Gleason score 5+4=9 MRIcT4N1M1b 4 PSA 1 4 PSAPAP 1 11.9 1 1.9-70 PSA33.32 ng/ml Gleason score 5+4=9 2006 5 10 570-8540 5-55 1 MRI2 3 ct4n1m1b 4 PSA NSAIDs 11 4 37.4
More information昭歯誌 indd
Dental Medicine Research 32 3 209 213, 2012 209 PET-CT PET-CT PET-CT 2006 8 2009 2 PET-CT 91 46 45 88 2 1 PET-CT 5 5.2 2 1 8 8.2 S 2 1 PET-CT Positron emission tomography-ct PET-CT 18 F-fluorodeoxy glucose
More information<4D6963726F736F667420506F776572506F696E74202D20328D528EEEE18796C68975899E939A82F09798977082B582BD82AA82F196C689758EA197C38DEC97708B408F988169967B8BB4905688EA9859298DC58F495B93C782DD8EE682E890EA97705D>
抗 腫 瘍 免 疫 応 答 を 利 用 したがん 免 疫 治 療 の 作 用 機 序 千 葉 大 学 大 学 院 医 学 研 究 院 免 疫 細 胞 医 学 本 橋 新 一 郎 2016 年 6 月 17 日 第 26 回 がん 臨 床 研 究 フォーラム 研 究 費 の 財 源 受 託 寄 付 科 学 研 究 費 その 他 ( ) 財 源 の 供 給 元 文 部 科 学 省 厚 生 労 働 省 AMED
More informationuntitled
( ) - 1 - - 2 - 38% 26% A) Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma 124 (J Clin Oncol 7: 126-131, 1989) 124 95 29 II 1 2,000mg/m 2 x 4 8g/m
More informationVOL.48 NO.5 Key words: locally advanced esophageal cancer, multimodality therapy, neo- adjuvant chemoradiotherapy
VOL.48 NO.5 Key words: locally advanced esophageal cancer, multimodality therapy, neo- adjuvant chemoradiotherapy MAY 2000 VOL.48 NO.5 MAY 2000 Table 2. Adverse events Toxicity was defined according to
More informationPowerPoint Presentation
Glioma 28% astrocytoma (WHO I) 0.28 anaplastic (WHO II/III) 0.18 Glioblastoma (WHO IV) 0.32 others 0.22 Meningioma partly malignant) 26% Pituitary adenoma 17% Neurinoma 11% Craniopharyngioma etc 5% Others
More information小児がん中央機関からの報告 1 情報提供 ( 院内がん登録 ) 国立がん研究センターがん対策情報センター センター長若尾文彦 1
小児がん中央機関からの報告 1 情報提供 ( 院内がん登録 ) 国立がん研究センターがん対策情報センター センター長若尾文彦 1 小児がん情報サービス更新 白血病 リンパ腫を4タブ化 2 横紋筋肉腫 :6 月 21 日更新 小児がん診療ガイドライン 2016 年版により 3 小児がんの解説 6 月更新予定 4 小児がん情報サービスアクセス状況 250,000 Google 検索アルゴリズム更改 200,000
More informationTl 99m Tc-MIBI 1 * * * * * 201 Tl 99m Tc-MIBI PSA ( ) 67 Ga PSA (490 ng/ml) (Bicalutamide) CT PSA PSA ( 40: , 2003) I. Whitmore 1) 2) 3
439 201 Tl 99m Tc-MIBI 1 * * * * * 201 Tl 99m Tc-MIBI PSA ( ) 67 Ga PSA (490 ng/ml) (Bicalutamide) CT PSA PSA ( 40: 439 443, 2003) I. Whitmore 1) 2) 3) 4) 5) 6) * 15 3 15 15 5 20 4 6 (0 650 0046) 201 Tl
More informationClinical Characteristics in Multiple Endocrine Neoplasia Type 1 in Japan: A review of 106 patients Katsuhiko YOSHIMOTO 1,2, Shiro SAITO 1 1. The First Department of Internal Medicine 2. Otsuka Department
More information44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)
(1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46
More informationi ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii
More informationMicrosoft Word - ○要旨集(校正2) 医甲147_王.docx
おう ほう 氏名王芳 学位の種類博士 ( 医学 ) 学位記番号 富医薬博甲第 147 号 学位授与年月日 平成 26 年 9 月 26 日 学位授与の要件 富山大学学位規則第 3 条第 3 項該当 教 育 部 名 富山大学大学院医学薬学教育部医学領域博士課程 生命 臨床医学専攻 学位論文題目 CD24+SSEA4+ ovarian carcinoma cells exhibit self -renewal
More information細胞増殖測定細胞染色プロトコル
Cell Counting Kit Cell Counting Kit -8 3 Cell Counting Kit -F -Cellstain- -Cellstain- -Cellstain- Calcein-AM solution -Cellstain- CytoRed solution -Cellstain- BCECF-AM special packaging -Cellstain- -Cellstain-
More information03_学術.indd
Arts and Sciences CT Approach to the incidental discovery of early-stage breast cancer on a chest CT 33393 Key words: Breast cancer. CT. Mammography Abstract Recently, we have treated two patients in our
More informationCSPOR CSPOR NEOS New primary Endocrine-therapy Origination Study 1 ~10%~ ~90%~ 2 CSPOR CSPOR ER/HER 3 N-SAS BC06 version CSPOR CSPOR St. Gallen
NEOS New primary Endocrine-therapy Origination Study 1 ~10%~ ~90%~ 2 ER/HER 3 4 St. Gallen ER/HER 5 6 Low risk n0 2 cm Grade 1 ER(+) and/or PgR(+) and HER2(-) 35 Intermediate n0 risk 2 cm Grade 2-3 ER(-)/PgR(-)
More informationGynecologic Oncology Trial and Investigation Consortium GOTIC-002
Gynecologic Oncology Trial and Investigation Consortium GOTIC-002 3 8 ...2...2...2...2...3...4...4...5...9...9...9...9...9... 13... 13... 13... 13... 13... 13... 13... 14... 14... 15... 15... 15...
More informationSekijuzi-27.indd
G-CSF 産生胃癌の既報告 38 例の解析 Key words G-CSF はじめに granulocyte-colony stimulating factor G-CSF Robinson G-CSF G-CSF Obara G-CSF G-CSF autocrine growth PubMED 方法 Morstyn G-CSF G-CSF G-CSF Shimamura G-CSF G-CSF.
More information1. Sugimura, T. and Fujimura, S.: Tumor production in glandular stomach of rat by N-methyl-N'-nitro- N-nitrosoguanidine. Nature, 216, 943-944, 1967. 2. Fujimura, S., Kogure, K., Sugimura, T. and Takayama,
More information明海大学歯学雑誌 40‐2☆/1.前川
J Meikai Dent Med 0, 7 79, 0 7 0 5 0 5 0 5. 0 5 8.5 5 7. Stage 8.0Stage 78.7Stage 5.Stage.8 Clinical Pathological Study of Malignant Neoplasm on 5 Cases in Our Department for past 0 years Katsuyuki INOUE,
More information序 がんの統計 15 年版が関係各位にご協力を頂き 発刊できましたことに感謝申し上げます 本書は わかりやすいがんの統計本 として1974 年から発刊しており 多くの方々に親しまれてきました 今日まで発刊された がんの統計 は貴重な資料が収録されており 日本人のがんの変貌を実感するとともに 正確な実
がんの統計 15 CACER STATISTICS I JAPA 215 公益財団法人がん研究振興財団 Foundation for Promotion of Cancer Research 序 がんの統計 15 年版が関係各位にご協力を頂き 発刊できましたことに感謝申し上げます 本書は わかりやすいがんの統計本 として1974 年から発刊しており 多くの方々に親しまれてきました 今日まで発刊された
More informationUnknown
Journal of Breast and Thyroid Sonology Journal of Breast and Thyroid Sonology Vol.3, No.3 July 2014 Original Article Clinical significance of classification of mixed-pattern tumor by breast ultrasound...
More information核44-4 (ガイドライン)-1
FDG-PET (2007) PET FDG PET * 2 * PET FDG PET PET/CT PET PET PET PET PET PET PET CT PET QOL PET PET PET PET 2 1. 2. 3. 4. 5. 6. 7. 8. 9. 9-1) 9-2) 9-3) FDG-PET 9-4) 9-5) A. CT B. PET/CT 9-6) MRI 9-7) 10.
More information解 析 対 象 患 者 PM SPM 174 例 固 形 がん 79 例 血 液 悪 性 腫 瘍 95 例 抗 がん 化 学 療 法 ± 放 射 線 療 法 6ヶ 月 以 上 固 形 がん 49 例 血 液 悪 性 腫 瘍 125 例 34 例 55 例 85 例 1984 年 1994 年 4 年
第 5 回 Hematological PET Club 総 会 がん 治 療 後 のsecond primary malignancy - 当 科 における 現 況 とPET/CTの 役 割 と 限 界 - 独 立 行 政 法 人 国 立 病 院 機 構 九 州 がんセンター 血 液 内 科 鵜 池 直 邦 14.9. ホテルグランビア 大 阪 Second primary malignancy(spm)とは
More informationスライド 1
1 2006 msv 2 2011 3 CT 2011 10mSv 10 40mSv 4 2012 217mSv 5 (CT) 2012 50 60mSv 6 2012 510mSv BRCA25 310 10mSv3% BRCA60-280% 3 5m Sv 1m Sv 12% . http://www.rea.or.jp/ire/pdf/report4.pdf 1.10 20 SMR 1.00
More informationGroup5 tub1 CT ct4b cn1 ch0 cp0 cm0 cstage a D3 A V Type5 muc tub1 pt4b pn1 1/28 No. 201 pstage a UFT/UZEL 5
91 113 117 2015 1 2015 2 4 2015 2 23 73 3 Group5 tub1 CT ct4b cn1 ch0 cp0 cm0 cstage a D3 A V Type5 muc tub1 pt4b pn1 1/28 No. 201 pstage a UFT/UZEL 5 22 Key words: Ⅰ 0.2 1 0.01 2 1 D3 1 Ⅱ 73 2012 12 Takeshi
More information原著・報告・記録(44行)/P261~274_報告 肝移植症例登録
261 Liver Transplantation in Japan Registry by the Japanese Liver Transplantation Society The Japanese Liver Transplantation Society Summary As of December 31, 2013, a total of 7,474 liver transplants
More informationLung Cancer diagnostic solutions
Lung Cancer diagnostic solutions 1 Lung Cancer diagnostic solutions 1 ALK D5F3 518-111175 790-4843 c-met SP44 518-108830 760-4430 SP65 518-109615 790-4467 CD56 MRQ-42 518-110710 760-4596 CEA TF3H8-1 2
More information2003 Giemsa HE HE AE1+AE3 HBME1 HE HE Well differentiated adenocarcinoma of colon Giemsa HE HE 62 Group V HE 47 Group V Peritoneal dissemination of gastric cancer HE 51 Poorly differentiated Adenocarcinoma(por2)
More informationⅡ Hb 4.1g/dl S LST G S ESD 10 S S 4 4 S D mL tub1 muc SS ly0 v0 PM0 DM0 N0 0/27 S tub1 tub2 SS
92 183 188 2016 1 1,2) 1) 1) 1) 1) 1) 3) 1) 2016 2 1 2016 3 11 84 S 2011 10 S 30 40 2 tub1 muc SS ly0 v0 PM0 DM0 N0 0/27 S 30 30 2 tub1 tub2 SS ly0 v0 PM0 DM0 N0 0/19 stage tub1 M ly0 v0 HM0 VM0 stage
More information序 がんの統計 17 版が関係各位のご協力を頂き 発刊できましたことに感謝申し上げます 本書は1974 年に発刊されて以来 44 年になりますが 日本人のがんの変貌を実感し 正確な実態把握によるがん対策の重要性が再認識されるものとして多くの方々に親しまれてきました 収載されている各種統計は 我が国の
ISS 2433-3212 がんの統計 17 CACER STATISTICS I JAPA 217 公益財団法人がん研究振興財団 Foundation for Promotion of Cancer Research 序 がんの統計 17 版が関係各位のご協力を頂き 発刊できましたことに感謝申し上げます 本書は1974 年に発刊されて以来 44 年になりますが 日本人のがんの変貌を実感し 正確な実態把握によるがん対策の重要性が再認識されるものとして多くの方々に親しまれてきました
More information原著・報告・記録(44行)/P156~169_報告 肝移植症例登録
156 Vol. 50, No. 23 Liver Transplantation in Japan Registry by the Japanese Liver Transplantation Society The Japanese Liver Transplantation Society Summary As of December 31, 2014, a total of 7,937 liver
More information原著・報告・記録(44行)/P134~147_報告 肝移植症例登録
134 Vol. 52, No. 23 Liver transplantation in Japan. Registry by the Japanese Liver Transplantation Society The Japanese Liver Transplantation Society Summary As of December 31, 2016, a total of 8,825 liver
More informationANALYSIS OF RADIOTHERAPY FOR LUMBOSACRAL CARCINOMATOUS NEUROPATHY Masatoshi TANIGUCHI, Yuko KANEYASU, Kumiko KARASAWA, Noboru FUKUHARA Makiko TANAKA,
ANALYSIS OF RADIOTHERAPY FOR LUMBOSACRAL CARCINOMATOUS NEUROPATHY Masatoshi TANIGUCHI, Yuko KANEYASU, Kumiko KARASAWA, Noboru FUKUHARA Makiko TANAKA, Midori KITA-Okawa, Tomohiko OKAWA (Received 8 December
More informationMedical Journal of Aizawa Hospital Medical Journal of Aizawa Hospital Vol. 10 (2012) Key words ö γ µ Graves disease and Hashimoto s thyroiditis are autoimmune thyroid diseases. Graves disease causes
More informationDiagnosis of cancer of the tongue and oral floor using plain CT Eiichiro ARIJI * and Shigenobu KANDA * Abstract : CT images of 18 patients, diagnosed squamous cell carcinomas of the tongue or oral floor,
More informationJ. Jpn. Stomatol. Soc. 39(1) : , January, 1990 Clinical and histopathological studies of combination therapy with Cisplatin and Peplomycin (PP t
J. Jpn. Stomatol. Soc. 39(1) : 175183, January, 1990 Clinical and histopathological studies of combination therapy with Cisplatin and Peplomycin (PP therapy) for the carcinoma of the tongue Iwai TOHNAI,
More information_02戸沢.indd
Akita J Med 43 : 79-86, 2016 15 1 1 1 1 2 2 3 4 4 1 2 3 4 received 19 July 2016, accepted 29 July 2016 Two cases of histological CR for squamous cell lung cancer with invasion to the pulmonary artery after
More information特集 Folia Pharmacol. Jpn. 142 PI3K/mTOR 新規がん治療薬の研究開発2 要約 PI K phosphatidyl inositol -kinase /mtor mammalian target of rapamycin PI K Akt mtor mtorc mto
特集 Folia Pharmacol. Jpn. 142 P3K/mTOR 新規がん治療薬の研究開発2 要約 P K phosphatidyl inositol -kinase /mtor mammalian target of rapamycin P K Akt mtor mtorc mtorc / P K/mTOR mtorc P K/mTOR 1. はじめに Bcr-Abl kinase multi
More information